Approved & therapeutic
Urofollitropin
Bravelle, Fostimon
Urofollitropin is follicle-stimulating hormone purified from the urine of postmenopausal women, used in assisted reproduction to stimulate follicular development. It is a urinary-derived alternative to recombinant FSH.
Also known as: Bravelle, Fostimon, uFSH, purified FSH
- Status
- Urofollitropin is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 32 to 37 hours after subcutaneous administration.
- How it's taken
- Subcutaneous or intramuscular injection
- Mechanism
- Reproductive axis (GnRH / kisspeptin / oxytocin)
- Pathways
- Estrogen
How Urofollitropin works
FSH acts on granulosa cells in the ovarian follicle to drive follicular growth and estradiol production. Urofollitropin is highly purified so that luteinising hormone activity is largely removed, giving predominantly FSH effect. In controlled ovarian stimulation it recruits multiple follicles rather than the single dominant follicle of a natural cycle.
What research has looked at
- Stimulates multiple follicular development for assisted reproductive technology.
- Purification removes most LH activity, allowing FSH effect to be titrated independently.
- A long clinical track record, predating recombinant gonadotropins.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Ovarian hyperstimulation syndrome, which can be severe and life-threatening, with ascites, haemoconcentration and thromboembolism.
- Multiple pregnancy, with its associated maternal and fetal risks.
- Ovarian torsion and ovarian enlargement.
- Injection-site reactions, abdominal pain and headache.
- It requires ultrasound and estradiol monitoring throughout the stimulation cycle; unmonitored use is unsafe.
Sources
- FDA approved-drug listing for urofollitropin · U.S. Food & Drug Administration
- DailyMed prescribing information for urofollitropin · NIH · DailyMed
- PubMed research on urofollitropin ovarian stimulation · NIH · National Library of Medicine
- DrugBank record for urofollitropin · DrugBank
Track Urofollitropin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Urofollitropin FAQ
What is Urofollitropin?
Urofollitropin is follicle-stimulating hormone purified from the urine of postmenopausal women, used in assisted reproduction to stimulate follicular development. It is a urinary-derived alternative to recombinant FSH.
How does Urofollitropin work?
FSH acts on granulosa cells in the ovarian follicle to drive follicular growth and estradiol production. Urofollitropin is highly purified so that luteinising hormone activity is largely removed, giving predominantly FSH effect. In controlled ovarian stimulation it recruits multiple follicles rather than the single dominant follicle of a natural cycle.
Is Urofollitropin FDA approved?
Yes. Urofollitropin is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Urofollitropin?
Reported half-life: Approximately 32 to 37 hours after subcutaneous administration.
How is Urofollitropin taken?
Subcutaneous or intramuscular injection.
What side effects have been reported with Urofollitropin?
Reported in the sources: Ovarian hyperstimulation syndrome, which can be severe and life-threatening, with ascites, haemoconcentration and thromboembolism; Multiple pregnancy, with its associated maternal and fetal risks; Ovarian torsion and ovarian enlargement; Injection-site reactions, abdominal pain and headache; It requires ultrasound and estradiol monitoring throughout the stimulation cycle; unmonitored use is unsafe.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.